Abstract
Neutrophil elastase (NE) is an innate immune cell-derived inflammatory mediator that we have shown increases the presentation of tumor-associated peptide antigens in breast cancer. In this study, we extend these observations to show that NE uptake has a broad effect on enhancing antigen presentation by breast cancer cells. We show that NE increases human leukocyte antigen (HLA) class I expression on the surface of breast cancer cells in a concentration and time-dependent manner. HLA class I upregulation requires internalization of enzymatically active NE. Western blots of NE-treated breast cancer cells confirm that the expression of total HLA class I as well as the antigen-processing machinery proteins TAP1, LMP2, and calnexin does not change following NE treatment. This suggests that NE does not increase the efficiency of antigen processing; rather, it mediates the upregulation of HLA class I by stabilizing and reducing membrane recycling of HLA class I molecules. Furthermore, the effects of NE extend beyond breast cancer since the uptake of NE by EBV–LCL increases the presentation of HLA class I-restricted viral peptides, as shown by their increased sensitivity to lysis by EBV-specific CD8+ T cells. Together, our results show that NE uptake increases the responsiveness of breast cancer cells to adaptive immunity by broad upregulation of membrane HLA class I and support the conclusion that the innate inflammatory mediator NE enhances tumor cell recognition and increases tumor sensitivity to the host adaptive immune response.
Original language | English (US) |
---|---|
Pages (from-to) | 741-751 |
Number of pages | 11 |
Journal | Cancer Immunology, Immunotherapy |
Volume | 65 |
Issue number | 6 |
DOIs | |
State | Published - Jun 1 2016 |
Funding
This work was supported by Grant R00CA133244 from the National Cancer Institute (NCI) (to Elizabeth A. Mittendorf), Leukemia SPORE CA100632 (to Jeffrey J. Molldrem), NCI P01 CA148600-01 (to Jeffrey J. Molldrem), Leukemia and Lymphoma Society Research Grant #6030-12 (to Jeffrey J. Molldrem), the T32 CA009599 training grant (to Akhil Chawla and Victor Gall) and the T32 CA009598 training grant (to Celine Kerros and Haley L. Peters) from the NCI. The Flow Cytometry and Cellular Imaging core were supported by Cancer Center Support Grant NCI #CA16672. STR DNA fingerprinting was done by the Cancer Center Support Grant funded Characterized Cell Line core, NCI #CA16672. Elizabeth A. Mittendorf is an R. Lee Clark Fellow of the University of Texas MD Anderson Cancer Center supported by the Jeanne F. Shelby Scholarship Fund. Gheath Alatrash and Elizabeth A. Mittendorf have contributed equally to this work. This work was supported by Grant R00CA133244 from the National Cancer Institute (NCI) (to Elizabeth A. Mittendorf), Leukemia SPORE CA100632 (to Jeffrey J. Molldrem), NCI P01 CA148600-01 (to Jeffrey J. Molldrem), Leukemia and Lymphoma Society Research Grant #6030-12 (to Jeffrey J. Molldrem), the T32 CA009599 training grant (to Akhil Chawla and Victor Gall) and the T32 CA009598 training grant (to Celine Kerros and Haley L. Peters) from the NCI. The Flow Cytometry and Cellular Imaging core were supported by Cancer Center Support Grant NCI #CA16672. STR DNA fingerprinting was done by the Cancer Center Support Grant funded Characterized Cell Line core, NCI #CA16672. Elizabeth A. Mittendorf is an R. Lee Clark Fellow of the University of Texas MD Anderson Cancer Center supported by the Jeanne F. Shelby Scholarship Fund. Gheath Alatrash and Elizabeth A. Mittendorf have contributed equally to this work.
Keywords
- Adaptive immunity
- Breast cancer
- HLA class I
- Neutrophil elastase
- Tumor-associated neutrophils
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology
- Cancer Research